Form 4 for KURA Kura Oncology, Inc.
Accepted 2026-06-22 18:00:03 ET · period of report 2026-06-18 · accession 0001193125-26-277780 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-22 18:00 | 2026-06-18 | KURA | Leoni Mollie | Chief Medical Off | S - Sale | $9.82 | -84.9K | 182.3K | -32% | -$834.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-18 | S | D | 84,929 | $9.82 | 182,345 | D | — | — | (F1) The shares sold were acquired by the Reporting Person upon vesting of restricted stock units and performance restricted stock units during the period from January 26, 2022 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. (F2) This transaction was executed in multiple trades at prices ranging from $9.56 to $9.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |